USPTO “clarifies” June 27, 2012 testimony on biologics exclusivity and India compulsory license

Deputy USPTO Director Teresa Stanek Rea has issued a retraction of her statement regarding Administration support for 12 years of exclusive rights in test data for biologic drugs, and moderated somewhat her statement on the India compulsory license for Nexavar. USTR also issued a statement on the issue of biologic test data in response to Rea’s earlier comments.

Continue Reading

Uncategorized

USPTO and Congress bash India over the Nexavar compulsory license

Teresa Stanek Rea On June 27, 2012, Teresa Stanek Rea, the Deputy Under Secretary of Commerce for Intellectual Property and the Deputy Director of the United States Patent and Trademark Office (USPTO), testified at a hearing on: “International IP Enforcement: Protecting Patents, Trade Secrets and Market Access”, before the US House of Representatives, Judicary Committee, Subcommittee on Intellectual Property, Competition, and the Continue Reading

Uncategorized

The European Orphan Works Directive: a missed opportunity?

Earlier this month, the European Parliament and the European Commission released a new compromise text on orphan works.

The Compromise Text is available here:
http://register.consilium.europa.eu/pdf/en/12/st10/st10953.en12.pdf

KEI sees the text as a step backwards for access to knowledge. The proposed directive makes far too many compromises, is too limited in terms of the beneficiaries and uses of works, and creates complicated, burdensome and costly procedures and record keeping requirements.

Background on earlier EU consultations

Continue Reading

Uncategorized

KEI letter to USTR regarding TPPA copyright provisions

The governments of Brunei, Chile, New Zealand, Singapore, Australia, Malaysia, Peru, Vietnam and the United States are negotiating a multilateral free trade agreement known as the Trans-Pacific Partnership Agreement (TPP). The negotiations are being conducted with considerable secrecy, even though they address many issues of great interest to the general public. The Agreement will cover many topics, including intellectual property rights, the pricing of pharmaceutical drugs, and the rights of investors to sue states over policies and actions that impact their investments. Continue Reading

Uncategorized

AUD $2 million Australia-WIPO MOU targets TIGAR, neglected diseases, developing IP systems and technology transfer

On 15 June 2012, the World Intellectual Property Organization and the Australian Permanent Mission to the World Trade Organization signed an agreement and released a joint communiqué “detailing how an AUD$2 million Australian contribution would assist least-developed and developing countries improve their intellectual property systems”.

Continue Reading

Uncategorized

Update: Global Fund responds to Report on William Steiger

The Global Fund just sent an email, which says that “your website which inaccurately reports that Mr Steiger will run VPP.” Here is the Global Fund email:

From: Andrew Hurst
Date: June 20, 2012 5:36:49 PM GMT+02:00
To: Thirukumaran Balasubramaniam Subject: RE: Question on the Global Fund’s Voluntary Pooled Procurement?

Dear Thiru

Further to our conversation this week, here is our statement:

Continue Reading